126 related articles for article (PubMed ID: 16438938)
1. Gelastatins and their hydroxamates as dual functional inhibitors for TNF-alpha converting enzyme and matrix metalloproteinases: synthesis, biological evaluation, and mechanism studies.
Park SK; Han SB; Lee K; Lee HJ; Kho YH; Chun H; Choi Y; Yang JY; Yoon YD; Lee CW; Kim HM; Choi HM; Tae HS; Lee HY; Nam KY; Han G
Biochem Biophys Res Commun; 2006 Mar; 341(2):627-34. PubMed ID: 16438938
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of TACE selective inhibitors: manipulations in the S1'-S3' pocket.
Huang A; Joseph-McCarthy D; Lovering F; Sun L; Wang W; Xu W; Zhu Y; Cui J; Zhang Y; Levin JI
Bioorg Med Chem; 2007 Sep; 15(18):6170-81. PubMed ID: 17606376
[TBL] [Abstract][Full Text] [Related]
3. Effects of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-alpha converting enzyme and matrix metalloproteinases, in a model of intestinal reperfusion injury in mice.
Souza DG; Ferreira FL; Fagundes CT; Amaral FA; Vieira AT; Lisboa RA; Andrade MV; Trifilieff A; Teixeira MM
Eur J Pharmacol; 2007 Sep; 571(1):72-80. PubMed ID: 17619015
[TBL] [Abstract][Full Text] [Related]
4. Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization.
Majka S; McGuire PG; Das A
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):260-6. PubMed ID: 11773040
[TBL] [Abstract][Full Text] [Related]
5. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
6. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.
Chun K; Park SK; Kim HM; Choi Y; Kim MH; Park CH; Joe BY; Chun TG; Choi HM; Lee HY; Hong SH; Kim MS; Nam KY; Han G
Bioorg Med Chem; 2008 Jan; 16(1):530-5. PubMed ID: 17936631
[TBL] [Abstract][Full Text] [Related]
7. Reactive site mutations in tissue inhibitor of metalloproteinase-3 disrupt inhibition of matrix metalloproteinases but not tumor necrosis factor-alpha-converting enzyme.
Wei S; Kashiwagi M; Kota S; Xie Z; Nagase H; Brew K
J Biol Chem; 2005 Sep; 280(38):32877-82. PubMed ID: 16079149
[TBL] [Abstract][Full Text] [Related]
8. Chronic hypoxia in the human neuroblastoma SH-SY5Y causes reduced expression of the putative alpha-secretases, ADAM10 and TACE, without altering their mRNA levels.
Marshall AJ; Rattray M; Vaughan PF
Brain Res; 2006 Jul; 1099(1):18-24. PubMed ID: 16762326
[TBL] [Abstract][Full Text] [Related]
9. Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17).
Budagian V; Bulanova E; Orinska Z; Ludwig A; Rose-John S; Saftig P; Borden EC; Bulfone-Paus S
J Biol Chem; 2004 Sep; 279(39):40368-75. PubMed ID: 15215246
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
Cherney RJ; Duan JJ; Voss ME; Chen L; Wang L; Meyer DT; Wasserman ZR; Hardman KD; Liu RQ; Covington MB; Qian M; Mandlekar S; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2003 May; 46(10):1811-23. PubMed ID: 12723945
[TBL] [Abstract][Full Text] [Related]
11. Alzheimer's amyloid precursor protein alpha-secretase is inhibited by hydroxamic acid-based zinc metalloprotease inhibitors: similarities to the angiotensin converting enzyme secretase.
Parvathy S; Hussain I; Karran EH; Turner AJ; Hooper NM
Biochemistry; 1998 Feb; 37(6):1680-5. PubMed ID: 9484239
[TBL] [Abstract][Full Text] [Related]
12. Multiple metalloproteinases process protransforming growth factor-alpha (proTGF-alpha).
Hinkle CL; Mohan MJ; Lin P; Yeung N; Rasmussen F; Milla ME; Moss ML
Biochemistry; 2003 Feb; 42(7):2127-36. PubMed ID: 12590602
[TBL] [Abstract][Full Text] [Related]
13. Pronounced diversity in electronic and chemical properties between the catalytic zinc sites of tumor necrosis factor-alpha-converting enzyme and matrix metalloproteinases despite their high structural similarity.
Solomon A; Rosenblum G; Gonzales PE; Leonard JD; Mobashery S; Milla ME; Sagi I
J Biol Chem; 2004 Jul; 279(30):31646-54. PubMed ID: 15102849
[TBL] [Abstract][Full Text] [Related]
14. Definition of peptide inhibitors from a synthetic peptide library by targeting gelatinase B/matrix metalloproteinase-9 (MMP-9) and TNF-α converting enzyme (TACE/ADAM-17).
Qiu Z; Yan M; Li Q; Liu D; Van den Steen PE; Wang M; Opdenakker G; Hu J
J Enzyme Inhib Med Chem; 2012 Aug; 27(4):533-40. PubMed ID: 21827363
[TBL] [Abstract][Full Text] [Related]
15. Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
Ott GR; Asakawa N; Liu RQ; Covington MB; Qian M; Vaddi K; Newton RC; Trzaskos JM; Christ DD; Galya L; Scholz T; Marshall W; Duan JJ
Bioorg Med Chem Lett; 2008 Feb; 18(4):1288-92. PubMed ID: 18234496
[TBL] [Abstract][Full Text] [Related]
16. Aldose reductase regulates high glucose-induced ectodomain shedding of tumor necrosis factor (TNF)-alpha via protein kinase C-delta and TNF-alpha converting enzyme in vascular smooth muscle cells.
Reddy AB; Ramana KV; Srivastava S; Bhatnagar A; Srivastava SK
Endocrinology; 2009 Jan; 150(1):63-74. PubMed ID: 18772236
[TBL] [Abstract][Full Text] [Related]
17. Acetylenic TACE inhibitors. Part 3: Thiomorpholine sulfonamide hydroxamates.
Levin JI; Chen JM; Laakso LM; Du M; Schmid J; Xu W; Cummons T; Xu J; Jin G; Barone D; Skotnicki JS
Bioorg Med Chem Lett; 2006 Mar; 16(6):1605-9. PubMed ID: 16426848
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of ADAM17 reduces hypoxia-induced brain tumor cell invasiveness.
Zheng X; Jiang F; Katakowski M; Kalkanis SN; Hong X; Zhang X; Zhang ZG; Yang H; Chopp M
Cancer Sci; 2007 May; 98(5):674-84. PubMed ID: 17355261
[TBL] [Abstract][Full Text] [Related]
19. Blockade of tumor necrosis factor-alpha-converting enzyme improves experimental small intestinal damage by decreasing matrix metalloproteinase-3 production in rats.
Matsumoto H; Koga H; Iida M; Tarumi K; Fujita M; Haruma K
Scand J Gastroenterol; 2006 Nov; 41(11):1320-9. PubMed ID: 17060126
[TBL] [Abstract][Full Text] [Related]
20. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
Levin JI; Du MT
Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
